A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.
about
Combination Therapy for Chronic Hepatitis B: Current IndicationsChronic hepatitis B: Advances in treatment.The Role of Interferon in Hepatitis B Therapy.Remodeling of B-Cell Subsets in Blood during Pegylated IFNα-2a Therapy in Patients with Chronic Hepatitis B Infection.Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.Genetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: A multicenter studyImpact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus.Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy?Antiviral drugs for HBV liver disease.Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review.Hepatitis B surface antigen monitoring and management of chronic hepatitis B.Why do I treat HBeAg-negative chronic hepatitis B patients with pegylated interferon?PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.HBeAg-negative chronic hepatitis B: why do I treat my patients with pegylated interferon-alfa?How to achieve immune control in chronic hepatitis B?Hepatitis B: treatment choice and monitoring for response and resistance.Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers.Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection.Tenofovir alafenamide for the treatment of chronic hepatitis B virus infection.The Efficacy and Safety of Peginterferon-α-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting.Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B: Role of host and viral factors associated with treatment response.Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B.Loss of HBsAg and antiviral treatment: from basics to clinical significance.Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected by pronounced serum HBsAg decline.Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.The multifaceted functions of ribavirin: antiviral, immunomodulator, or both?Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment.Drugs in Development for Hepatitis B.Efficacy and tolerability of pegylated interferon-α-2a in chronic hepatitis B: A multicenter clinical experienceProgression and status of antiviral monitoring in patients with chronic hepatitis B: From HBsAg to HBV RNA
P2860
Q24604492-119379E0-7C8A-484D-9C92-0DEBFC5A7942Q33660010-ABF6CEF9-C00F-4841-B46B-B0D466CF6ACEQ34154958-C72256C9-62C8-4317-AF3A-525E9BC1088FQ36046859-234AAA75-6376-4F4C-A2CC-A3315CE13144Q36062523-C601CF23-C2AC-48DB-A6B4-D78773A2B227Q36309024-20397D96-61D9-43AD-B272-CD455C7D6ECFQ37411318-32795A58-2EE8-4752-BFB0-A4A9E1548FFAQ37825532-9B2F5DA3-593A-43CD-99F9-BB7DA499CB2AQ37825909-58BD248D-4834-43DF-863C-7C111001CC39Q37866717-D5BC9319-42C6-4E9B-80A0-B0C64D205A45Q37892655-E5CF4D0F-EDF2-477C-BFC9-01497235A6FBQ38071402-47DC72D1-0AC5-47F4-92C6-E07D92CFDD31Q38102776-240DECDD-8BFC-45CA-ADA3-5D47D8BAD732Q38174261-D3C23B96-EF27-485F-8216-FBCED553041AQ38383489-604291A7-FFAD-4D81-B865-AE017795F110Q38707903-84C50DFE-40B9-45A5-A797-727FA633791FQ38811832-8DAC26CD-3991-440A-AB28-B7A9755685BAQ38928531-0F2E9C2F-BE44-4CAA-9CDC-D57943F1AE91Q39275759-FC2AFCD8-40AE-43AD-9183-B4A7E253C70FQ39284357-5B68014A-49DA-4E5A-BDAC-904A3274B314Q40172735-0D61345A-567F-4F9C-BB10-C057E5AFEC67Q41342289-31E725BD-38F0-4BA1-8FC8-861472F1A0D2Q42200827-FB526277-71CB-4F7F-A783-AA768EF188BAQ42235230-26F8DF6B-8707-4E6B-AD12-0D2A182117FDQ42242300-5ED65C0E-271E-439E-9480-B8733D64E02BQ42947260-0AEEEDE0-995E-47C4-A58E-7495EF10AA86Q43034060-8F48C492-66DF-4B88-BE74-9051723DF402Q52669049-E31B8463-CF4B-41A2-9377-7C292A1D7AFDQ52764230-8920AB90-A71F-4EAB-A75D-1E8106E642E8Q57387055-9BB3DCDA-3821-4A2F-BD16-E7622A6AF828Q57491223-DC6CDF01-A9C7-47E8-8EE0-06679DE89555
P2860
A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
A randomized trial of peginter ...... -negative chronic hepatitis B.
@en
A randomized trial of peginter ...... -negative chronic hepatitis B.
@nl
type
label
A randomized trial of peginter ...... -negative chronic hepatitis B.
@en
A randomized trial of peginter ...... -negative chronic hepatitis B.
@nl
prefLabel
A randomized trial of peginter ...... -negative chronic hepatitis B.
@en
A randomized trial of peginter ...... -negative chronic hepatitis B.
@nl
P2093
P2860
P50
P356
P1476
A randomized trial of peginter ...... -negative chronic hepatitis B.
@en
P2093
Anneke J van Vuuren
Elke Verhey
Fehmi Tabak
Harry L A Janssen
Maria Raptopoulou-Gigi
Meral Akdogan
Necati Ormeci
PARC Study Group
Peter Ferenci
Pieter E Zondervan
P2860
P304
P356
10.1038/AJG.2010.186
P407
P577
2010-05-11T00:00:00Z